Stocks
News
ETFs
Economy
Currencies
Press Releases
Articles from OMEICOS Therapeutics GmbH
OMEICOS Therapeutics Announces Positive Phase 2 Study Outcome Demonstrating OMT-28’s Potential in Primary Mitochondrial Diseases (PMD)
Trial Results Support Transition into Late-Stage Development with Program Expected to be Phase 2b/3-ready in H2 2026
By
OMEICOS Therapeutics GmbH
· Via
GlobeNewswire
· January 29, 2026
OMEICOS Therapeutics Completes Enrollment of PMD-OPTION Study in Primary Mitochondrial Disease
Interim data confirms OMT-28’s strong safety profile in PMD patients, top-line data expected mid-2025
By
OMEICOS Therapeutics GmbH
· Via
GlobeNewswire
· September 26, 2024
Articles from OMEICOS Therapeutics GmbH | MarketMinute
